Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma.

被引：0
|
作者：
Maiese, Eric
Graham, Christopher N.
Hawe, Emma
Le Moine, Jean-Gabriel
机构：
[1] Janssen Sci Affairs, LLC, Horsham, PA USA
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] RTI Hlth Solut, Manchester, Lancs, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e20037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20037
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Richardson, P. G.
    Trudel, S.
    Popat, R.
    Mateos, M-, V
    Vangsted, A. J.
    Ramasamy, K.
    Martinez-Lopez, J.
    Quach, H.
    Orlowski, R. Z.
    Arnao, M.
    Lonial, S.
    Karanes, C.
    Pawlyn, C.
    Kim, K.
    Oriol, A.
    Berdeja, J. G.
    Rodriguez Otero, P.
    Casas-Aviles, I
    Spirli, A.
    Poon, J.
    Li, S.
    Gong, J.
    Wong, L.
    Lamba, M.
    Pierce, D. W.
    Amatangelo, M.
    Peluso, T.
    Maciag, P.
    Katz, J.
    Pourdehnad, Michael
    Bahlis, Nizar J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (11): : 1009 - 1022
  • [32] Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
    Dubey, A. P.
    Khatri, Sameer
    Maggo, Sachin
    Singh, Nilabh K.
    Sharma, Durgesh
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (06) : 846 - 849
  • [33] Cost per Progression Free Survival (PFS) of Daratumumab, Elotuzumab, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (DRd, ERd, KRd, IRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Santana, Pamela
    Saad, Ricardo
    Kolanian, Adrielle
    Fioratti, Cyntia
    Junqueira, Marcela
    Decimoni, Tassia
    BLOOD, 2019, 134
  • [34] Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
    Dimopoulos, Meletios A.
    San-Miguel, Jesus
    Belch, Andrew
    White, Darrell
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Morton, James
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Kaufman, Jonathan L.
    Sutherland, Heather J.
    Lalancette, Marc
    Magen, Hila
    Iida, Shinsuke
    Kim, Jin Seok
    Prince, H. Miles
    Cochrane, Tara
    Oriol, Albert
    Bahlis, Nizar J.
    Chari, Ajai
    O'Rourke, Lisa
    Wu, Kaida
    Schecter, Jordan M.
    Casneuf, Tineke
    Chiu, Christopher
    Soong, David
    Sasser, A. Kate
    Khokhar, Nushmia Z.
    Avet-Loiseau, Herve
    Usmani, Saad Z.
    HAEMATOLOGICA, 2018, 103 (12) : 2088 - 2096
  • [35] Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.
    Weisel, Katja C.
    Miguel, Jesus San
    Cook, Gordon
    Leiba, Merav
    Suzuki, Kenshi
    Kumar, Shaji
    Cavo, Michele
    Avet-Loiseau, Herve
    Quach, Hang
    Hungria, Vania
    Lentzsch, Suzanne
    Hajek, Roman
    Sonneveld, Pieter
    Wu, Kaida
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma
    Richard, Shambavi
    Jagannath, Sundar
    Cho, Hearn Jay
    Parekh, Samir
    Madduri, Deepu
    Richter, Joshua
    Chari, Ajai
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (01) : 31 - 45
  • [37] Cyclophosphamide, bortezomib, and dexamethasone (CYBORD) treatment for relapsed/refractory multiple myeloma.
    Monge, Jorge
    Kortuem, K. Martin
    Stewart, A. Keith
    Bergsagel, P. Leif
    Mikhael, Joseph
    Reeder, Craig B.
    Mayo, Angela
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): final overall survival analysis
    Yong, Kwee
    Martin, Thomas
    Dimopoulos, Meletios
    Mikhael, Joseph
    Capra, Marcelo
    Facon, Thierry
    Hajek, Roman
    Spicka, Ivan
    Baker, Ross
    Kim, Kihyun
    Martinez, Gracia
    Min, Chang-Ki
    Pour, Ludek
    Leleu, Xavier
    Oriol, Albert
    Koh, Youngil
    Suzuki, Kenshi
    Casca, France
    Mace, Sandrine
    Risse, Marie-Laure
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S30 - S31
  • [39] ECONOMIC EVALUATION OF CARFILZOMIB plus LENALIDOMIDE plus DEXAMETHASONE (KRD) VS LENALIDOMIDE plus DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (R/RMM)
    Fonseca, R.
    Panjabi, S.
    Campioni, M.
    Giannopoulou, A.
    Benedict, A.
    Houisse, I.
    Aggarwal, S.
    Jakubowiak, A.
    HAEMATOLOGICA, 2016, 101 : 526 - 526
  • [40] CARFILZOMIB AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL AND RESPONSE RATES VS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS (PTS) WITH RELAPSED MULTIPLE MYELOMA (RMM): THE PHASE 3 STUDY ENDEAVOR
    Dimopoulos, M.
    Moreau, P.
    Palumbo, A.
    Joshua, D.
    Pour, L.
    Hajek, R.
    Facon, T.
    Ludwig, H.
    Oriol, A.
    Goldschmidt, H.
    Rosinol, L.
    Straub, J.
    Suvorov, A.
    Araujo, C.
    Rimashevskaya, E.
    Pika, T.
    Gaidano, G.
    Weisel, K.
    Goranova-Marinova, V.
    Schwarer, A.
    Minuk, L.
    Masszi, T.
    Karamanesht, I.
    Offidani, M.
    Hungria, V.
    Spencer, A.
    Gillenwater, H.
    Mohamed, N.
    Feng, S.
    Chng, W. J.
    HAEMATOLOGICA, 2015, 100 : 336 - 336
12345